$Fulgent Genetics (FLGT.US)$Revenue surged by 12 times in 20...
$Fulgent Genetics (FLGT.US)$Revenue surged by 12 times in 2020, continued to grow by 1.4 times in 2021, typical pandemic stock. In 2022, there was a significant decline of 37.6%. Operating profit also reached a peak of 0.68 billion in 2021, then dropped sharply by 73% in 2022. Net income saw a substantial decrease of 72% in 2022.
Revenue declined by 79% in Q1 2023, both operating profit and net income entered into a loss range. Currently, the market cap is 1.15 billion, lacking investment value.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.